Analysts See $-0.33 EPS for Kindred Biosciences, Inc. (KIN); CRYO-CELL INTERNATIONAL (CCEL) Shorts Down By 33.33%

February 16, 2018 - By Marie Mckinney

CRYO-CELL INTERNATIONAL INCORPORATED (OTCMKTS:CCEL) had a decrease of 33.33% in short interest. CCEL’s SI was 200 shares in February as released by FINRA. Its down 33.33% from 300 shares previously. With 1,200 avg volume, 0 days are for CRYO-CELL INTERNATIONAL INCORPORATED (OTCMKTS:CCEL)’s short sellers to cover CCEL’s short positions. The stock decreased 2.21% or $0.2 during the last trading session, reaching $8.85. About shares traded. Cryo-Cell International, Inc. (OTCMKTS:CCEL) has 0.00% since February 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Kindred Biosciences, Inc. (NASDAQ:KIN) to report $-0.33 EPS on March, 7.They anticipate $0.04 EPS change or 13.79% from last quarter’s $-0.29 EPS. After having $-0.29 EPS previously, Kindred Biosciences, Inc.’s analysts see 13.79% EPS growth. It closed at $8.55 lastly. It is down 71.15% since February 16, 2017 and is uptrending. It has outperformed by 54.45% the S&P500.

Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with focus on the collection and preservation of umbilical cord blood stem cells for family use. The company has market cap of $62.86 million. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. It has a 26.9 P/E ratio. The firm also makes and sells Prepacyte CB units, a technology used to process umbilical cord blood stem cells.

Investors sentiment decreased to 2.24 in Q3 2017. Its down 0.52, from 2.76 in 2017Q2. It turned negative, as 5 investors sold Kindred Biosciences, Inc. shares while 12 reduced holdings. 10 funds opened positions while 28 raised stakes. 18.28 million shares or 11.16% more from 16.44 million shares in 2017Q2 were reported. Goldman Sachs Gp reported 48,932 shares. Zacks Invest Management owns 23,795 shares or 0% of their US portfolio. Renaissance Technology Ltd Liability Corp holds 0.01% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 826,800 shares. Ajo L P owns 312,586 shares. Schwab Charles Inv Mngmt owns 35,500 shares or 0% of their US portfolio. Wells Fargo And Mn accumulated 337,608 shares or 0% of the stock. D E Shaw And reported 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). 40,769 were accumulated by California State Teachers Retirement System. Eam Invsts Limited holds 0.07% or 65,487 shares. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 3,707 shares. Park West Asset Mgmt Ltd Liability Corporation has 2.41% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 5.16 million shares. National Bank & Trust Of America De stated it has 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). General accumulated 0.5% or 666,467 shares. Sg Americas Secs Limited holds 15,690 shares or 0% of its portfolio. 15,580 were accumulated by Millennium Ltd Limited Liability Company.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $240.96 million. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Among 7 analysts covering Kindred Biosciences (NASDAQ:KIN), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Kindred Biosciences had 11 analyst reports since November 17, 2015 according to SRatingsIntel. The rating was downgraded by KeyBanc Capital Markets to “Sector Weight” on Friday, November 18. The firm has “Buy” rating given on Tuesday, May 30 by FBR Capital. The rating was initiated by C.L. King on Wednesday, December 27 with “Hold”. Ladenburg Thalmann initiated the shares of KIN in report on Tuesday, November 1 with “Buy” rating. BMO Capital Markets maintained the shares of KIN in report on Monday, August 7 with “Hold” rating. The firm earned “Buy” rating on Tuesday, June 27 by FBR Capital. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, November 17.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News